KRAS and lung cancer: The in silico results of the comparative interaction of a natural molecule against a chemically designed one like 3144, and the one that projects as an inhibitor of the RAS protein upon binding to the surface of switch 1, altered the active state of the mutant protein to an off state, causing the inhibition of tumor growth and of the viability of cells of pancreatic, colon, and lung cancer [59], suggesting PSK’s anticancer effect by presenting an interaction with the surface of switch 1 in K-RAS.